SMYD3 is a histone methyltransferase, an enzyme that adds chemical tags to histone proteins around which DNA is wound, thereby influencing which genes are switched on. It was first characterized as a methyltransferase for histone H3 lysine 4 and H4 lysine 5, associated with RNA polymerase complexes and the activation of genes governing proliferation, cell cycle progression and epithelial-mesenchymal transition. But SMYD3 also methylates non-histone proteins, modulating signaling pathways involved in cell survival, stemness and self-renewal. Crucially, the enzyme is overexpressed in many tumor types, including colorectal, breast, pancreatic and lung cancers, hepatocellular carcinoma and gastric cancer, where its levels correlate with aggressive biological behavior and poor prognosis. The new study builds on the team’s earlier work showing that SMYD3 physically interacts with the DNA repair proteins ATM, CHK2 and BRCA2 and is required for the repair of double-strand breaks, the lesions in which both strands of the DNA helix are severed simultaneously.

To define the clinical landscape, the researchers first mined data from 407 stomach adenocarcinoma samples in The Cancer Genome Atlas Pan-Cancer Atlas cohort. Tumors were split into SMYD3-high and SMYD3-low groups based on mRNA levels, and their genomes were annotated for clinically actionable alterations using the OncoKB precision oncology database. The result was striking: SMYD3-high tumors showed significant mutual exclusivity with actionable alterations in PTEN, ATM and BRCA2, as well as with ERBB2 amplification, high microsatellite instability or tumor mutation burden, and MTAP deletion. In other words, tumors that overproduce SMYD3 rarely carry the genomic hallmarks that currently guide targeted therapy, and more than half of them lacked any actionable alteration at all. This positions SMYD3 overexpression as a defining feature of a patient subgroup that today has few precision options, and it suggests that SMYD3 itself could serve as both a biomarker and a drug target for this population.

The mechanistic core of the study relied on an ingenious experimental system. The team engineered AGS gastric cancer cells, which rank among the highest SMYD3-expressing gastric lines in the DepMap database, to carry a version of the AsiSI endonuclease fused to an estrogen receptor domain. Adding the hormone analog 4-hydroxytamoxifen shuttles the enzyme into the nucleus, where it cuts the genome at roughly 150 predetermined sites, generating a synchronized wave of double-strand breaks whose chromatin environment can be interrogated with base-pair precision. Using chromatin immunoprecipitation followed by quantitative PCR, the researchers showed that SMYD3 itself is recruited to homologous recombination-prone break sites, and that its recruitment is abolished by EM127, a potent covalent SMYD3 inhibitor developed through medicinal chemistry work published in 2022.

What happens at the break site when SMYD3 is active turned out to be a coordinated choreography of histone marks. Within hours of damage induction, the enzyme’s activity was required for the enrichment of H4K20me2, a dimethylation mark critical for the earliest recognition of DNA damage, and for H3K9me3, a trimethylation mark that in turn recruits the acetyltransferase TIP60 to deposit H4K16ac, another modification essential for repair. Blocking SMYD3 significantly reduced all three marks at damaged chromatin. Interestingly, H3K79me2, a mark that can compensate for H4K20me2 loss, rose when SMYD3 was inhibited, hinting that cells attempt a backup remodeling program when the primary pathway fails. Downstream of the chromatin changes, the recruitment of the entire homologous recombination machinery, including RAD50, ATM, CHK2, BRCA1, RPA32, BRCA2 and RAD51, was markedly impaired by SMYD3 inhibition, while the repair sensor 53BP1 was also reduced at a non-homologous end joining-prone break site. When the team monitored repair kinetics after treatment with the DNA-breaking agent neocarzinostatin, both pharmacological inhibition and genetic silencing of SMYD3 left cells littered with unresolved gamma-H2AX foci, the microscopic signatures of unrepaired breaks.

The study then identified the molecular switch that activates SMYD3 during repair. Bioinformatic prediction across four phosphorylation-site algorithms pointed to threonine 22, a surface-exposed residue, as the most likely ATM target. Mass spectrometry of recombinant SMYD3 phosphorylated by ATM in vitro confirmed T22 as the residue modified, and a custom antibody raised against the phospho-T22 epitope, validated by enzymatic dephosphorylation, revealed that the modification appears in AGS cells after DNA damage, disappears when ATM is blocked with KU60019 or SMYD3 is silenced, and, critically, is detectable in tumor samples from gastric cancer patients who had received neoadjuvant chemotherapy, which induces double-strand breaks and activates ATM in vivo. Co-immunoprecipitation experiments showed that phospho-T22-SMYD3 associates with phospho-ATM, CHK2, BRCA2 and RAD51, whereas a phospho-deficient T22A mutant failed to bind the repair complex altogether. Cells forced to rely on the T22A mutant proliferated less after DNA damage and showed elevated cleaved PARP, a hallmark of apoptosis, demonstrating that this single phosphorylation event is essential for both repair complex assembly and survival.

Functionally, SMYD3 inhibition proved to be a selective strike against homologous recombination. In the DR-GFP reporter assay, both siRNA knockdown and EM127 treatment reduced HR efficiency in AGS cells, while a luciferase-based assay showed only a partial impairment of non-homologous end joining. That asymmetry is the key to the therapeutic strategy: PARP inhibitors exploit exactly this kind of repair imbalance, and they work best in tumors whose homologous recombination is already defective, a state known as BRCAness. By pharmacologically imposing BRCAness on HR-proficient tumors, SMYD3 inhibition should widen the applicability of PARP inhibitors beyond the BRCA-mutated setting. The data bore this out. In high-SMYD3 AGS and NCI-N87 cells, combining EM127 with olaparib or with rucaparib, another clinically relevant PARP inhibitor currently in gastric cancer trials, dramatically reduced proliferation and increased cell death, confirmed by PARP cleavage, whereas low-SMYD3 KATOIII cells were largely unresponsive, underscoring SMYD3 expression as a predictive biomarker.

Perhaps the most clinically resonant result came from a model of acquired resistance. The researchers generated an olaparib-resistant derivative of the HGC-27 gastric cancer line by chronic exposure to escalating drug concentrations over six months. Resistant cells displayed significantly increased nuclear SMYD3 compared with the parental line, suggesting the enzyme helps mediate PARP inhibitor resistance. When SMYD3 was inhibited with EM127, or silenced genetically, olaparib sensitivity was restored, with PARP cleavage rising sharply. The combination also worked in three-dimensional settings that better mimic real tumors: gastric tumorspheres, which showed elevated SMYD3 alongside the stemness markers KLF4 and OCT4, were killed far more effectively by the dual treatment than by either drug alone, and the same held true for olaparib-resistant tumorspheres.

The final layer of evidence came directly from patients. Working with surgical specimens from gastric cancer patients at the IRCCS Saverio de Bellis Research Hospital in Castellana Grotte, the team used droplet digital PCR to stratify tumors by SMYD3 expression, finding elevated levels in roughly half of the samples analyzed, and grew matched normal and tumor organoids from the SMYD3-high cases. These patient-derived tumor organoids retained their tumor-specific molecular profile, with enrichment of the epithelial marker EpCAM and reduction of CDH1, reflecting loss of epithelial integrity and invasiveness. Treating them with EM127 plus olaparib or rucaparib produced marked cell death and PARP cleavage, mirroring the two-dimensional and tumorsphere results. Taken together, the findings delineate a complete arc from molecular mechanism to translational opportunity: ATM phosphorylates SMYD3 at threonine 22 in response to DNA damage, phosphorylated SMYD3 remodels chromatin at break sites to assemble the homologous recombination machinery, and blocking this cascade sensitizes SMYD3-high gastric cancers, including PARP inhibitor-resistant ones, to synthetic lethality. If the strategy advances toward clinical testing, SMYD3 expression could guide patient selection, extending the benefits of PARP inhibition to a subgroup of gastric cancer patients who currently have no targeted option.

Subject of Research: SMYD3-dependent chromatin remodeling in DNA double-strand break repair and its targeting for epigenetics-based therapy of gastric cancer

Article Title: Targeting the DNA-repair chromatin-modifier protein SMYD3 as a novel epigenetics-based therapy for gastric cancer

Article References: De Marco, K., Latrofa, M., Forte, G., Lepore Signorile, M., Di Nicola, E., Sanese, P., Fasano, C., Disciglio, V., Candela, E., Coletta, S., Grossi, V., & Simone, C. (2026). Targeting the DNA-repair chromatin-modifier protein SMYD3 as a novel epigenetics-based therapy for gastric cancer. Journal of Experimental & Clinical Cancer Research, 45(1), Article 202. https://doi.org/10.1186/s13046-026-03823-2

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03823-2

Keywords: gastric cancer, SMYD3, histone methyltransferase, DNA damage response, homologous recombination, double-strand breaks, ATM, PARP inhibitors, synthetic lethality, epigenetics, patient-derived organoids, drug resistance

The concept of BRCAness has dominated precision oncology discussions of DNA damage response defects for more than a decade. Tumors with loss of homologous recombination repair, the high-fidelity pathway that accurately fixes double-stranded DNA breaks, become exquisitely vulnerable to agents that create or exploit such breaks, including platinum drugs like oxaliplatin and cisplatin and PARP inhibitors such as olaparib. This logic works well for tumors with BRCA1 or BRCA2 mutations. However, ATM and CHEK2 mutations tell a different story. ATM, the gene encoding ataxia-telangiectasia mutated kinase, sits at the apex of a signaling cascade that coordinates the cellular response to DNA damage, orchestrating cell cycle checkpoints and the recruitment of repair machinery. CHEK2, encoding the checkpoint kinase 2 that acts downstream of ATM, is part of the same pathway. Crucially, defects in this pathway do not necessarily abolish homologous recombination repair itself, which means that tumors carrying ATM or CHEK2 mutations may retain enough repair capacity to withstand platinum and PARP-inhibitor therapy.

The research team, led by investigators at the Medical College of Wisconsin’s LaBahn Pancreatic Cancer Program together with collaborators at Wayne State University’s Karmanos Cancer Institute, approached the problem from two complementary directions. First, they mined an institutional real-world database to identify patients with advanced or metastatic pancreatic ductal adenocarcinoma whose tumors harbored ATM or CHEK2 mutations, assembling a cohort of 16 patients whose treatment histories spanned 48 separate lines of chemotherapy. Second, they turned to the laboratory, where they used CRISPR gene editing to create a panel of isogenic PANC-1 pancreatic cancer cell lines carrying either homozygous or heterozygous knockout of ATM. The cell lines were allele-verified by whole-exome sequencing, ensuring that any differences in drug response could be attributed specifically to the degree of ATM loss rather than to background genetic variation between different cell models.

The clinical results were striking. When the researchers compared the outcomes of second-line treatments for these ATM or CHEK2-mutant patients, irinotecan-containing regimens outperformed every other therapeutic category, including the platinum-based and PARP-inhibitor-containing combinations that the BRCAness framework would have predicted to be most effective. The median progression-free survival on irinotecan-based second-line therapy was 11.5 months, compared with just 3 months for the other treatment types, a difference that reached statistical significance with a p value below 0.001. In a disease where median survival is typically measured in months and treatment options after first-line failure are limited, an eight-and-a-half-month difference in disease control represents a clinically meaningful advance for this molecularly defined subgroup.

The laboratory experiments provided a mechanistic explanation for this clinical observation. The researchers exposed their isogenic cell line panel to SN-38, the active metabolite of irinotecan, which the liver generates from the prodrug in patients. SN-38 works by poisoning topoisomerase I, an enzyme that relieves torsional stress in DNA by creating transient single-strand breaks during replication and transcription. When topoisomerase I is inhibited, the enzyme becomes trapped on DNA as covalent topoisomerase I-DNA adducts, and the collision of these adducts with advancing replication forks generates double-stranded breaks that require an intact DNA damage response to resolve. Preliminary work had suggested that certain forms of ATM pathway dysfunction might prevent the removal of these topoisomerase I-DNA adducts, allowing the lesions to persist and accumulate into lethal genomic instability.

The CRISPR-edited panel confirmed this dose-dependent relationship with remarkable precision. In colony formation assays, the homozygous ATM knockout cells showed a half-maximal inhibitory concentration, or IC50, of just 0.3 nanomolar for SN-38, while the heterozygous knockout cells showed an IC50 of 0.8 nanomolar and the wild-type controls an IC50 of 7 nanomolar. In other words, complete loss of ATM rendered the cells more than twenty-fold more sensitive to the drug than unedited cells, and even the loss of a single ATM copy, which better models the heterozygous mutations frequently seen in patient tumors, conferred nearly nine-fold sensitization. Proliferation and viability assays told the same story, with all comparisons reaching statistical significance at p values below 0.01. The graded response across the isogenic panel demonstrates that the degree of ATM loss directly determines the degree of topoisomerase I inhibitor sensitivity.

These findings carry substantial implications for the clinical management of pancreatic cancer. Currently, comprehensive genomic profiling of pancreatic tumors routinely identifies ATM and CHEK2 mutations, and many oncologists extrapolate from the BRCA literature to offer platinum chemotherapy or PARP inhibitors to these patients. The new data suggest that this extrapolation may be misguided for a meaningful proportion of the ATM pathway-mutant population, since these tumors may not exhibit homologous recombination repair deficiency and may therefore not respond consistently to those agents. Instead, the study proposes that topoisomerase I inhibition exploits a distinct vulnerability: the inability of ATM-defective cells to process the stalled topoisomerase I-DNA complexes that SN-38 generates. Irinotecan is already an established component of the liposomal irinotecan combination used in second-line metastatic pancreatic cancer, which makes the prospect of biomarker-guided deployment particularly practical.

The study’s design also highlights the growing value of pairing real-world evidence with engineered laboratory models. The clinical cohort, while modest in size at 16 patients and 48 chemotherapy lines, was drawn from institutional protocols approved by the Medical College of Wisconsin Institutional Review Board, including the MCW Master Predict observational program registered as NCT05802069, and reflects the actual treatment decisions and outcomes recorded in routine care. Because each patient served in part as their own comparison across different treatment lines, the analysis captures the heterogeneity of real clinical practice while still permitting a statistically robust comparison. The isogenic CRISPR-edited cell lines then provided the controlled experimental system that retrospective clinical data can never offer, isolating the effect of ATM dosage on drug sensitivity with allele-level verification.

Several caveats temper the enthusiasm. The clinical cohort was small, and retrospective real-world analyses are inherently susceptible to selection biases in how patients were assigned to different treatments. The laboratory work relied on a single pancreatic cancer cell line background, PANC-1, albeit engineered with rigor, and in vitro sensitivity to SN-38 does not guarantee that the pharmacokinetics, toxicity profile, and combination effects of irinotecan in patients will mirror the dish. The authors themselves are careful to frame their conclusions as hypothesis-generating, calling for prospective investigation of topoisomerase I inhibitors in ATM pathway-mutated pancreatic ductal adenocarcinoma rather than claiming an immediate change to standards of care. Nonetheless, the convergence of a large clinical signal, a statistically significant survival difference, and a clean dose-dependent molecular mechanism is exactly the kind of evidence that justifies launching biomarker-stratified clinical trials.

Looking forward, the study opens several avenues. Antibody-drug conjugates that deliver topoisomerase I inhibitors selectively to tumor cells are an increasingly prominent class of anticancer agents, and the mechanistic logic established here suggests that ATM pathway status could serve as a predictive biomarker for such drugs across multiple tumor types, not only pancreatic cancer. More broadly, the work challenges the field to move beyond the binary of homologous recombination proficiency and deficiency, recognizing that different DNA damage response defects create different, drug-specific vulnerabilities. For the five to ten percent of pancreatic cancer patients whose tumors carry ATM or CHEK2 mutations, the message is one of cautious optimism: a therapy already in the clinic may work far better in their specific molecular context than anyone had previously demonstrated, and prospective trials to confirm that promise may not be far behind.

Subject of Research: Sensitivity of ATM/CHEK2-mutant pancreatic ductal adenocarcinoma to topoisomerase I inhibition

Article Title: Beyond BRCAness: ATM pathway defects confer sensitivity to topoisomerase I inhibition

Article References: Kamgar, M., McFall, T., Mehdi, M., Thapa, B., Szabo, A., Ahmed, G., Davidson, R., Scheuber, G., Shreenivas, A., Thomas, J. P., Sriram, D., Evans, D. B., Tsai, S., Christians, K. K., Erickson, B., Hall, W. A., Chen, H.-Z., Lytle, N., Sarkar, N. D., … Kurzrock, R. (2026). Beyond BRCAness: ATM pathway defects confer sensitivity to topoisomerase I inhibition. Genome Medicine. https://doi.org/10.1186/s13073-026-01774-z

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01774-z

Keywords: ATM, CHEK2, pancreatic cancer, irinotecan, SN-38, topoisomerase I inhibitor, DNA damage response, BRCAness, CRISPR, precision oncology, progression-free survival, homologous recombination repair

Checkpoint kinase 2, encoded by the CHEK2 gene, sits at a pivotal node in the DNA damage response. When breaks are detected, the master transducer ATM phosphorylates checkpoint kinase 2, which in turn propagates the alarm by phosphorylating a panel of downstream targets, including the tumor suppressor p53, the checkpoint regulator BRCA1 and the cell-cycle effector CDC25A. The result is a coordinated halt in cell division that buys time for repair, or, if the damage is beyond salvation, steers the cell toward senescence or apoptosis. Because biallelic loss-of-function mutations in CHEK2 confer a substantially elevated risk of breast cancer and other malignancies, understanding precisely what the kinase does, and what cells do without it, has occupied genome stability researchers for more than two decades.

The central question addressed in the new work is one of pathway choice. Mammalian cells deploy two principal strategies to mend double-strand breaks. Homologous recombination is the high-fidelity route: it uses the intact sister chromatid as a template and is largely restricted to the S and G2 phases of the cell cycle, when such a template exists. Non-homologous end joining, by contrast, can operate throughout the cell cycle. It directly religates broken ends, quickly but with the potential for small insertions or deletions at the junction. A third pathway, alternative end joining or microhomology-mediated end joining, relies on short exposed sequence repeats and is generally considered more error-prone still. Which pathway a cell engages for any given break has profound consequences: homologous recombination preserves the genetic message, while the end-joining routes can quietly rewrite it.

Pathway choice is not random. It is orchestrated by a molecular choreography that begins with the rapid accumulation of the MRE11-RAD50-NBS1 complex and the signaling protein 53BP1 at break sites. A tug-of-war then ensues. 53BP1, together with its effectors RIF1 and the shieldin complex, blocks the nucleolytic resection of DNA ends, thereby favoring end joining. BRCA1, in combination with PALB2 and BRCA2, promotes the removal of 53BP1 and supports the long-range resection that generates the single-stranded DNA overhangs required for homologous recombination. Cell-cycle cues, chromatin state and the availability of key enzymes all tilt this balance. Checkpoint kinase 2 has long been suspected of influencing the process, both through its well-characterized phosphorylation of BRCA1 and through its role in enforcing the cell-cycle checkpoints that determine whether a sister chromatid template is even available.

According to the study, checkpoint kinase 2 deficiency measurably affects how cells engage these repair pathways after DNA damage. Rather than a simple loss of repair capacity, the deficiency appears to shift the relative engagement of the competing routes, altering the balance between resection-dependent, template-directed repair and direct end joining. This distinction matters because a cell can maintain apparently adequate bulk repair throughput while quietly accumulating a different spectrum of errors. The work suggests that the kinase functions not merely as an amplifier of the damage signal but as a determinant of repair-pathway engagement, embedding cell-cycle and damage-load information into the repair decision itself.

The experimental logic behind such conclusions typically rests on a combination of genetic manipulation and reporter assays. Researchers induce defined double-strand breaks with site-specific nucleases or ionizing radiation, then measure the relative use of homologous recombination and end joining with engineered fluorescent or antibiotic-resistance reporters in which restoration of a disrupted gene depends on a specific repair route. Complementary biochemical readouts, including chromatin immunoprecipitation for repair factors such as RAD51, 53BP1 and RIF1, and assays of single-stranded DNA generation at break sites, reveal how the recruitment landscape changes when checkpoint kinase 2 is absent. Cell-cycle fractionation is essential, since the phases in which homologous recombination is available are exactly the phases most affected by checkpoint loss, and the new study’s emphasis on engagement rather than raw capacity points to analyses of this kind.

Why should a signaling kinase have a hand in pathway choice at all? One likely answer lies in the temporal logic of the DNA damage response. Checkpoint kinase 2 activation is among the earliest events after a break occurs, and its phosphorylation of CDC25A triggers the degradation of that phosphatase, preventing cells from entering or progressing through S phase while breaks persist. This checkpoint function is intimately tied to resection biology: productive homologous recombination requires time, a sister chromatid and a permissive cell-cycle window, all of which are guaranteed by an intact checkpoint. Without checkpoint kinase 2, cells may proceed into or through S phase with unrepaired breaks, encounter lesions without an appropriate template context, and default more heavily toward end-joining mechanisms that demand no such coordination. The kinase’s phosphorylation of BRCA1, meanwhile, has been implicated in recruiting and stabilizing the recombination machinery at damage sites, providing a second, more direct link to pathway selection.

The clinical resonance of these findings is difficult to overstate. CHEK2 is one of the most frequently mutated moderate-risk breast cancer susceptibility genes identified to date, carried by a meaningful fraction of women in population cohorts across Europe and North America. If loss of the kinase biases cells toward error-prone repair in specific contexts, that bias could help explain why CHEK2 carriers accumulate oncogenic mutations over a lifetime, and why their tumors display characteristic patterns of genomic scarring. There is also a therapeutic dimension. Inhibitors of poly(ADP-ribose) polymerase exploit the dependence of BRCA-deficient tumors on alternative repair routes, and a refined understanding of how checkpoint kinase 2 loss reshapes pathway engagement could inform whether CHEK2 mutation carriers respond differently to PARP inhibitors, radiation or certain chemotherapeutics that inflict DNA damage deliberately.

The study also speaks to a broader conceptual shift in genome biology. For many years, the DNA damage response was portrayed as a linear circuit: damage in, signal transduced, repair out. The contemporary picture is far more networked, with feedback loops, phase-specific constraints and kinetic competition among repair factors deciding the fate of each lesion. Checkpoint kinases were initially assigned narrow roles as clock-setters, pausing the cycle while repair proceeded. The accumulating evidence, including the pathway-engagement effects documented in this study, suggests instead that signaling and repair are intertwined at the level of mechanism, not merely sequence. The kinase does not simply buy time for repair; it helps determine which repair will occur.

Open questions remain. The precise phosphorylation events that link checkpoint kinase 2 to the resection machinery are still being mapped, and the extent to which the pathway-choice effects seen in cell models generalize to human tissues bearing heterozygous CHEK2 mutations, the situation in most carriers, awaits further investigation. It will also be important to determine whether the altered repair balance in checkpoint kinase 2-deficient cells produces the mutation signatures now detectable in tumor genomes, allowing epidemiologists to connect carrier status to specific patterns of somatic evolution. What the study establishes is that a deficiency in checkpoint kinase 2 changes not just the speed of the cellular response to double-strand breaks but its character, tilting the molecular tug-of-war that decides whether the genome’s severed strands are stitched back together faithfully or patched in ways that leave a permanent, and potentially dangerous, record. In the ongoing effort to understand why some inherited variants so potently predispose to cancer, that shift in repair engagement may prove to be one of the most consequential consequences of losing this guardian of the genome.

The study’s timing is notable given renewed interest in checkpoint kinases as drug targets. Selective checkpoint kinase 2 inhibitors have been explored in oncology, partly on the premise that transient checkpoint loss can sensitize tumors to DNA-damaging agents by forcing cells to divide before repair is complete. The observation that the kinase influences which repair route is engaged adds a further consideration: pharmacological inhibition might not simply accelerate breakage-driven death in cancer cells but could also reshape repair choices in exposed normal tissue, a variable worth measuring in preclinical safety work.

The findings may also intersect with tissue-specific mutation patterns seen in CHEK2 families. Unlike BRCA1 and BRCA2, which confer pronounced ovarian cancer risk, CHEK2 mutations are associated predominantly with breast cancer, with weaker or uncertain links to other tumor types. A repair-pathway explanation would predict that the consequences of losing the kinase depend on how often a given tissue relies on the routes whose engagement is altered, offering a framework for those epidemiological differences.

Methodologically, distinguishing a genuine shift in pathway engagement from a secondary consequence of checkpoint failure remains analytically demanding. Because checkpoint loss changes cell-cycle distributions, apparent differences in reporter outcomes can reflect altered timing rather than altered mechanism, making properly controlled, phase-matched comparisons essential for interpreting this and future studies of signaling kinases in repair decisions.

Subject of Research: The role of checkpoint kinase 2 in DNA double-strand break repair pathway choice

Article Title: Checkpoint kinase 2 deficiency affects the engagement of DNA double-strand break repair pathways following DNA damage

Article References: Muñoz-Maldonado, C., Etter, R., Quintin, A., Degen, P. M., Medo, M., Aebersold, D. M., Zimmer, Y., & Medová, M. (2026). Checkpoint kinase 2 deficiency affects the engagement of DNA double-strand break repair pathways following DNA damage. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03340-3

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03340-3

Keywords: checkpoint kinase 2, CHEK2, DNA double-strand breaks, homologous recombination, non-homologous end joining, DNA damage response, BRCA1, ATM, genome stability, cancer susceptibility, pathway choice, DNA repair

The research team, led by scientists at the Mahavir Cancer Sansthan and Research Centre in Patna along with collaborators across several Indian institutions, enrolled nine women from the arsenic-endemic districts of Saran, Buxar and Bhojpur. These participants were selected on the basis of the highest blood arsenic concentrations recorded in earlier surveys conducted in the region. Each woman provided samples of blood, urine and breast milk, which were acid-digested in the laboratory and analyzed for total arsenic using graphite furnace atomic absorption spectrometry, a technique sensitive enough to detect the element at concentrations below one-tenth of a microgram per liter.

The exposure data were sobering. Every one of the nine women carried blood arsenic levels above the ten micrograms per liter reference threshold, with the highest measured value reaching an extraordinary 491.2 micrograms per liter. Six of the nine exceeded the CDC’s permissible limit of fifty micrograms per liter in urine, peaking at 921.4 micrograms per liter, a pattern consistent with ongoing exposure through drinking water and locally grown food. Most alarming for public health was the breast milk analysis: eight of the nine lactating women showed arsenic concentrations above the one microgram per liter reference level set by a joint WHO/IAEA collaborative study, with a maximum of 438.6 micrograms per liter. Because breast milk represents a direct exposure pathway for nursing infants, the authors highlight this as evidence of potential maternal-to-infant transfer during a uniquely vulnerable window of development.

To probe what such sustained toxic burden might be doing at the genomic level, the team turned to whole exome sequencing, a next-generation sequencing approach that captures and reads all protein-coding regions of the genome. This strategy is well suited to the task because more than eighty-five percent of known disease-causing variants reside in exons. DNA extracted from each participant’s peripheral blood was prepared using targeted capture libraries and sequenced on an Illumina platform with paired-end chemistry, achieving mean coverage depths above eighty-five to one hundred times. Variants were called following the Genome Analysis Toolkit best-practices framework, aligned to the GRCh38 human reference genome, and classified according to the American College of Medical Genetics and Genomics guidelines using population frequency databases such as gnomAD and the 1000 Genomes Project alongside computational prediction tools including SIFT, PolyPhen-2, MutationTaster and Mutation Assessor.

Out of the nine women sequenced, two carried notable variants in genes that sit at the heart of genomic maintenance. Subject 1 harbored a novel heterozygous missense variant in the MSH6 gene, designated c.3716 T>C (p.Ile1239Thr), located in exon 8 on chromosome 2. The substitution replaces isoleucine with threonine at codon 1239 within a protein that, together with MSH2, forms the MutSα complex responsible for recognizing replication errors during DNA synthesis. Computational algorithms predicted the change to be damaging, and the affected nucleotide showed strong evolutionary conservation across one hundred vertebrate species, yet the variant is absent from all individuals in gnomAD and the 1000 Genomes Project. Under ACMG criteria it was classified as a variant of uncertain significance, a label reflecting both its suspicious features and the current limits of scientific evidence.

Subject 2 carried an even more concerning alteration: a heterozygous missense variant in the ATM gene, c.590G>A (p.Gly197Glu), in exon 6 on chromosome 11. This change, swapping glycine for glutamic acid at codon 197, was predicted damaging by both SIFT and PolyPhen-2, with the glycine residue conserved across all mammalian species examined. The variant is extremely rare, observed in only seven of 30,766 South Asian alleles in gnomAD and absent entirely from the 1000 Genomes cohort. Critically, it was classified as likely pathogenic under ACMG guidelines. The ATM gene encodes a master checkpoint kinase of the PI3/PI4-kinase family that orchestrates the cellular response to DNA double-strand breaks, phosphorylating tumor suppressors such as p53 and BRCA1, the checkpoint kinase CHK2, and the DNA repair protein NBS1. Variants in ATM have been associated with hereditary cancer susceptibility, and the remaining seven participants showed no clinically notable exomic alterations.

The biological significance of these two genes makes their disruption in arsenic-exposed individuals particularly noteworthy. MSH6 is a cornerstone of the mismatch repair pathway, working in concert with MSH2, MLH1 and PMS2 to excise mispaired bases and preserve fidelity during cell division. Germline MSH6 mutations are a recognized cause of Lynch syndrome, the most common hereditary colorectal cancer predisposition condition, and a meta-analysis of twenty-seven studies found MSH6 mutations in roughly seven percent of colorectal and nearly ten percent of endometrial cancer cases. Prior experimental work has shown that MSH6 also interacts with Ku70 to regulate non-homologous end joining of double-strand breaks, and that Msh6-deficient mice accumulate mutation frequencies up to five-fold higher than controls, particularly after ionizing radiation. Arsenic’s toxicological mechanism, meanwhile, is known to generate reactive oxygen species that inflict oxidative DNA damage, including 8-oxoG lesions that mismatch repair helps to process in cooperation with the SETD2 methyltransferase and the ATM signaling pathway.

The authors are careful to frame the findings as hypothesis-generating rather than conclusive. With only nine participants, no unexposed control group, and no matched tissue samples to distinguish somatic from germline variants, the study cannot establish a causal or dose-response relationship between arsenic burden and DNA repair gene mutation. Indeed, several women with equally severe arsenic exposure showed no detectable genomic alterations, hinting that individual genetic background, arsenic metabolism profiles and hormonal factors may shape who develops molecular damage. Sex-specific differences in arsenic methylation capacity, reflected in varying ratios of methylated metabolites, could help explain why women represent a potentially under-recognized high-risk group for environmentally driven cancers, including colorectal cancer, which the researchers identify as a particular concern in chronically exposed populations.

Even within those limits, the study’s integrated design, pairing multi-matrix toxicology with exome-wide sequencing, points toward a new model for environmental health surveillance. The detection of potentially pathogenic variants that conventional screening would miss underscores the value of genomic approaches in exposed communities, and the breast milk findings add an urgent transgenerational dimension, since arsenic has been shown in animal models to induce epigenetic alterations that can be inherited across generations. The research team calls for larger cohort studies incorporating matched controls, functional validation of the identified variants through mismatch repair assays, ATM kinase signaling measurements and CRISPR-based modeling, and exploration of epigenetic silencing in ATM and MSH6. If validated, these molecular markers could serve as early-warning biomarkers of arsenic-induced carcinogenesis, enabling targeted screening and precision public health interventions for the estimated ten million people in Bihar alone who live with poisoned groundwater, and millions more worldwide who share the same invisible exposure.

Beyond the immediate findings, the study sits within a broader epidemiological landscape. Chronic arsenic exposure through groundwater is estimated to affect well over one hundred million people worldwide, with South Asia bearing a disproportionate share of the burden. The metalloid is classified as a Group 1 human carcinogen, and epidemiological work across Bangladesh, India and parts of South America has linked prolonged exposure not only to cancers of the skin, bladder, lung and colorectum, but also to cardiovascular disease and reproductive toxicity. What distinguishes the present research is its attempt to move from population-level risk statistics toward the individual molecular events that may underlie them.

The choice of sequencing platform also merits attention. Unlike targeted gene panels, which interrogate a predefined set of loci, whole exome sequencing permits the discovery of rare, novel or compound variants that no a priori hypothesis would have flagged. It additionally opens the door to mutational signature analysis, in which distinctive patterns of base substitution can be matched to specific mutagenic processes, including the oxidative stress that arsenic is known to induce through reactive oxygen species generation. Such signatures, once validated, could serve as fingerprints of environmental carcinogenesis within a tumor or normal tissue genome.

The breast milk results carry particular weight for regional health policy. Arsenic is efficiently methylated in the body to mono- and dimethylated species, and interindividual variation in this metabolism is thought to influence both retention in tissues and excretion into milk. If lactational transfer proves to be a consistent pathway, interventions such as provision of arsenic-safe drinking water to nursing mothers, nutritional supplementation, and routine screening of breast milk in endemic districts could become practical priorities alongside existing water decontamination programs.

Ultimately, the work illustrates how environmental toxicology and clinical genomics can be woven together at small scale to generate testable hypotheses. Larger cohorts with matched unexposed controls, longitudinal sampling and functional assays will be needed to determine whether the DNA repair variants observed here are truly arsenic-driven, incidental, or markers of broader genomic instability in exposed communities.

Subject of Research: Whole exome sequencing of women chronically exposed to arsenic through contaminated groundwater to identify DNA repair gene variants

Article Title: Whole exome sequencing reveals DNA repair gene variants in women exposed to chronic arsenic poisoning

Article References: Agarwal, R., Kumar, A., Pandey, T., Verma, D., Kumar, K., Chayal, N. K., Ali, M., Srivastava, A., Verma, K. S., Kumar, D., Sharma, A., Singh, M., & Ghosh, A. K. (2026). Whole exome sequencing reveals DNA repair gene variants in women exposed to chronic arsenic poisoning. Discover Toxicology, 3(1), Article 15. https://doi.org/10.1007/s44339-026-00059-9

Image Credits: AI Generated

DOI: 10.1007/s44339-026-00059-9

Keywords: arsenic poisoning, whole exome sequencing, DNA repair genes, MSH6, ATM, groundwater contamination, breast milk arsenic, Bihar India, colorectal cancer risk, genotoxicity, mismatch repair, environmental health